We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+16.69%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$176M
AUM Growth
+$30.3M
(+21%)
Cap. Flow
+$13.4M
Cap. Flow
% of AUM
7.61%
Top 10 Holdings %
Top 10 Hldgs %
46.67%
Holding
67
New
5
Increased
34
Reduced
5
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Veracyte
VCYT
|
+$3.07M |
| 2 |
Vanda Pharmaceuticals
VNDA
|
+$2.72M |
| 3 |
AtriCure
ATRC
|
+$2.39M |
| 4 |
AngioDynamics
ANGO
|
+$2.11M |
| 5 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$2.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TLGT
Teligent, Inc
TLGT
|
+$4.59M |
| 2 |
Sanofi
SNY
|
+$2.13M |
| 3 |
ABCO
Advisory Board Co
ABCO
|
+$1.69M |
| 4 |
SPPI
Spectrum Pharmaceuticals Inc
SPPI
|
+$1.4M |
| 5 |
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
|
+$806K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.57% |
| 2 | Consumer Staples | 0.89% |
| 3 | Financials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AtriCure
ATRC
$1.92B
| $12.7M | 7.2% |
636,170
+139,499
| +28% | +$2.39M |
|
2
NeoGenomics
NEO
$1.96B
| $11.2M | 6.34% |
2,683,090
+192,242
| +8% | +$883K |
|
|
SPNC
3
DELISTED
Spectranetics Corp
SPNC
| $10.8M | 6.12% |
312,258
+20,134
| +7% | +$628K |
|
|
AKRX
4
DELISTED
Akorn Inc
AKRX
| $8.42M | 4.77% |
232,692
+19,180
| +9% | +$740K |
|
5
Harvard Bioscience
HBIO
$27.5M
| $8.01M | 4.54% |
141,272
+34,888
| +33% | +$1.66M |
|
|
SRGA
6
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $7.35M | 4.17% |
47,127
+2,484
| +6% | +$358K |
|
|
NXTM
7
DELISTED
NxStage Medical Inc.
NXTM
| $6.69M | 3.79% |
373,164
+26,987
| +8% | +$435K |
|
|
TLGT
8
DELISTED
Teligent, Inc
TLGT
| $6.46M | 3.66% |
73,446
-49,004
| -40% | -$4.59M |
|
|
ENZ
9
DELISTED
Enzo Biochem, Inc.
ENZ
| $5.39M | 3.05% |
1,213,901
+77,326
| +7% | +$369K |
|
|
ARRY
10
DELISTED
Array Biopharma Inc
ARRY
| $5.34M | 3.03% |
1,129,560
+70,290
| +7% | +$278K |
|
11
Ligand Pharmaceuticals
LGND
$5.76B
| $4.36M | 2.47% |
131,369
+8,954
| +7% | +$291K |
|
12
Alkermes
ALKS
$8.22B
| $4.15M | 2.35% |
70,861
+5,438
| +8% | +$277K |
|
13
QuidelOrtho
QDEL
$1.14B
| $4.14M | 2.35% |
143,092
+10,207
| +8% | +$277K |
|
14
Omnicell
OMCL
$1.61B
| $3.99M | 2.26% |
120,485
+9,294
| +8% | +$287K |
|
|
STRM
15
DELISTED
Streamline Health Solutions
STRM
| $3.91M | 2.22% |
60,249
+3,835
| +7% | +$227K |
|
|
ELGX
16
DELISTED
Endologix Inc
ELGX
| $3.83M | 2.17% |
25,037
+1,877
| +8% | +$234K |
|
|
17
Veracyte
VCYT
$3.7B
| $3.81M | 2.16% |
+393,926
| New | +$3.07M |
|
|
OXFD
18
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $3.73M | 2.11% |
273,473
+83,707
| +44% | +$1.14M |
|
|
NVDQ
19
DELISTED
Novadaq Technologies Inc.
NVDQ
| $3.71M | 2.1% |
222,899
+14,778
| +7% | +$211K |
|
|
20
AngioDynamics
ANGO
$611M
| $3.7M | 2.1% |
194,512
+124,690
| +179% | +$2.11M |
|
21
Bio-Techne
TECH
$11.2B
| $3.63M | 2.05% |
156,972
+10,708
| +7% | +$245K |
|
|
22
Vanda Pharmaceuticals
VNDA
$307M
| $3.29M | 1.87% |
+229,818
| New | +$2.72M |
|
23
Celldex Therapeutics
CLDX
$2.99B
| $2.8M | 1.59% |
10,241
+720
| +8% | +$179K |
|
24
STAAR Surgical
STAA
$1.21B
| $2.79M | 1.58% |
306,381
+21,651
| +8% | +$210K |
|
25
Standard BioTools
LAB
$340M
| $2.72M | 1.54% |
80,613
+6,131
| +8% | +$174K |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q4 2014 Portfolio in Review
As of Q4 2014, First Light Asset Management held 67 positions worth $176M, up 21% from $146M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
First Light Asset Management deployed $13.4M of net new capital in Q4 2014, opening 5 new positions and adding to 34 existing holdings. Its largest new stake was Veracyte: 393,926 shares worth $3.81M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the largest reduction was Teligent, Inc, an estimated $4.59M trimmed.
- First Light Asset Management's largest Q4 2014 buy was Veracyte: 393,926 shares worth $3.81M.
- First Light Asset Management added most to AtriCure in Q4 2014, an estimated $2.39M increase.
- First Light Asset Management's biggest Q4 2014 reduction was Teligent, Inc, cutting an estimated $4.59M.
- First Light Asset Management fully exited Advisory Board Co in Q4 2014, selling an estimated $1.69M.
- First Light Asset Management's ten largest holdings make up 47% of its $176M portfolio in Q4 2014.
- First Light Asset Management opened 5 new positions and closed 1 in Q4 2014.
- First Light Asset Management's portfolio value rose 21% quarter-over-quarter to $176M.
Based on First Light Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.